> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letter
- URL: https://www.fdaweb.com/latest-fda-warning-letter-10/
- Published: 2020-11-24T12:00:00.000Z
- Updated: 2026-09-14T16:37:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148162

FDA has posted its latest batch of Warning Letters that includes one medical product company. It can be accessed by clicking on the link following the summary below:

**AuroLife Pharma**, Dayton, NJ (10/16): FDA inspected the firm 1/13-2/12 and found significant GMP violations for finished pharmaceuticals. For example, AuroLife failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications. It also failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair. Additionally, the firm failed to establish and follow written procedures for cleaning and maintaining equipment. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aurolife-pharma-llc-607087-10162020?ref=fdaweb.com).